Unknown

Dataset Information

0

Diverse HIV-1 escape pathways from broadly neutralizing antibody PGDM1400 in humanized mice.

ABSTRACT: Recent studies have shown the potential of broadly neutralizing antibodies (bnAbs) for HIV-1 treatment. One of the candidate antibodies moving into clinical trials is the bnAb PGDM1400. Here, we studied the therapeutic potency and escape pathways of bnAb PGDM1400 during monovalent therapy in human immune system (HIS) mice using the BG505, REJO, MJ4 and AMC008 virus isolates. PGDM1400 administered during chronic infection caused a modest decrease in viral load in the first week of administration in 7 out of 10 animals, which correlated with the in vitro neutralization sensitivity of the viruses to PGDM1400. As expected for monotherapy, viral loads rebounded after about a week and different viral escape pathways were observed, involving the deletion of glycans in the envelope glycoprotein at positions 130 or 160. (Pre)clinical trials should reveal whether PGDM1400 is a useful component of an antibody combination treatment or as part of a tri-specific antibody.

SUBMITTER: van der Velden YU 

PROVIDER: S-EPMC7755169 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Recent studies have shown the potential of broadly neutralizing antibodies (bnAbs) for HIV-1 treatment. One of the candidate antibodies moving into clinical trials is the bnAb PGDM1400. Here, we studied the therapeutic potency and escape pathways of bnAb PGDM1400 during monovalent therapy in human immune system (HIS) mice using the BG505, REJO, MJ4 and AMC008 virus isolates. PGDM1400 administered during chronic infection caused a modest decrease in viral load in the first week of administration  ...[more]

Similar Datasets

Unknown Efficacy of broadly neutralizing monoclonal antibody PG16 in HIV-infected humanized mice.
| S-EPMC4125441 | biostudies-literature
Unknown Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies.
| S-EPMC6117093 | biostudies-literature
Unknown Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.
| S-EPMC3494733 | biostudies-other
Unknown Humanized Immunoglobulin Mice: Models for HIV Vaccine Testing and Studying the Broadly Neutralizing Antibody Problem.
| S-EPMC5914178 | biostudies-literature
Unknown Long-Term Persistence of Anti-HIV Broadly Neutralizing Antibody-Secreting Hematopoietic Cells in Humanized Mice.
| S-EPMC6318702 | biostudies-literature
Unknown Comprehensive Mapping of HIV-1 Escape from a Broadly Neutralizing Antibody.
| S-EPMC5512576 | biostudies-literature
Unknown Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge.
| S-EPMC5337964 | biostudies-literature
Unknown Heterologous prime-boost vaccination drives early maturation of HIV broadly neutralizing antibody precursors in humanized mice.
| S-EPMC11233128 | biostudies-literature
Unknown Multiple pathways of escape from HIV broadly cross-neutralizing V2-dependent antibodies.
| S-EPMC3624332 | biostudies-literature
Unknown HIV therapy by a combination of broadly neutralizing antibodies in humanized mice.
| S-EPMC3809838 | biostudies-literature